×   Holy Name (main site)   School of Nursing   HNH Fitness   Villa Marie Claire   Simulation Learning   HN Medical Partners

List of Clinical Studies

 201-541-6312   |    info@holyname.org

Learn more about our studies


Study Name
MK7902-001 – A Multicenter, Open-label, Randomized Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab versus Treatment of Physician’s Choice in Participants with Advanced Endometrial Cancer. Hypothesis is that combination therapy leads to improved progression-free survival.
Read more.

Principal Investigator
Sharyn Lewin, MD


Study Name
MK3475-775 – A Phase 3 Randomized, Open-label, Study of Pembrolizumab (MK-3475) Plus Levantinib versus Chemotherapy for First-Line Treatment of Advanced or Recurrent Endometrial Carcinoma. Hypothesis is that the combination for pembrolizumab plus Levantinib is superior to chemotherapy with respect to progression-free survival.
Read more.

Principal Investigator
Sharyn Lewin, MD


Study Name
GOG-3039 – A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer.
Read more.

Principal Investigator
Sharyn Lewin, MD


Study Name
AZ DUO-E – A Randomized, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer
Read more.

Principal Investigator
Maria Schiavone, MD

Study Name
FIRST – A Randomized, double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer. Hypothesis is that TSR-042 and Niraparib produces a deeper response and prolonged progression-free survival.
Read more.

Principal Investigator
Sharyn Lewin, MD


Study Name
MK7339-001 – A randomized phase 3, double-blind study of chemotherapy with or without Pembrolizumab followed by maintenance with Olaparib or placebo for the first-line treatment of BRCA non-mutated advanced epithelial ovarian cancer.
Read more.

Principal Investigator
Maria Schiavone, MD


Study Name
QPT-ORE-005 – A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
Read more.

Principal Investigator


Study Name
LAE002INT2001 – An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cance
Read more.

Principal Investigator


Study Name
IMGN853-0416 – A randomized, open-label, phase 3 study of Mirvetuximab Soravtansine vs. investigator's choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression (MIRASOL)
Read more.

Principal Investigator
Sharyn Lewin, MD


Study Name
IMGN853-0417 – A phase 3, single arm study of Mirvetuximab Soravtansine in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha expression (SORAYA)
Read more.

Principal Investigator
Sharyn Lewin, MD


Study Name
AVB500-OC-004 - A phase 3, randomized, double-blind, adaptive, placebo/Paclitaxel-controlled study of AVB-S6-500 in combination with Paclitaxel in patients with platinum-resistant recurrent ovarian cancer (ARAVIVE)
Read more.

Principal Investigator
Sharyn Lewin, MD


Inspiring Patient Stories

The Patricia Lynch Cancer Center provides the best care to every patient. Here our some of their stories.

Previous Next